Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5616-5623

  Kredo, T ^a,e   Mauff, K ^a,c   Van Der Walt, J S ^a,d   Wiesner, L ^a   Maartens, G ^a,b   Cohen, K ^a,b   Smith, P ^a,b   Barnes, K I ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UPPSALA UNIVERSITY   (Sweden)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOATING; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FLUORENES; HIV INFECTIONS; HIV-1; HUMANS; MALARIA; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 81555206726     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05265-11     Document Type: Article

References (44)

1. Aarnoutse, R. E. 2003. Combination of nelfinavir/ritonavir and nevirapine in a once daily antiretroviral regimen for healthy volunteers. Ph.D. thesis. University Medical Centre Nijmegen, Nijmegen, Netherlands.
2. Ashley, E. A., et al. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
3. Ashley, E. A., et al. 2007. Pharmacokinetic study of artemether- lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12:201-208.
4. Asimus, S., and T. Gordi. 2007. Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Br. J. Clin. Pharmacol. 63:758-762. (Pubitemid 46753577)
5. Back, D., S. Gibbons, and S. Khoo. 2003. Pharmacokinetic drug interactions with nevirapine. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1):S8-S14. (Pubitemid 37158628)
6. Barnes, K. I., W. M. Watkins, and N. J. White. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 24:127-134.
7. Checchi, F., et al. 2006. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar. J. 5:59.
8. Cohen, K., et al. 2008. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J. Antimicrob. Chemother. 61:389-393.
9. Denis, M. B., et al. 2006. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11:1800-1807. (Pubitemid 44813874)
10. de Vries, P. J., and T. K. Dien. 1996. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 52:818-836.
11. Dondorp, A. M., et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
12. Ezzet, F., R. Mull, and J. Karbwang. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561. (Pubitemid 28522119)
13. Ezzet, F., M. van Vugt, F. Nosten, S. Looareesuwan, and N. J. White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704. (Pubitemid 30117964)
14. Reference deleted.
15. German, P., et al. 2009. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr. 51:424-429.
16. Giao, P. T., and P. J. de Vries. 2001. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40:343-373.
17. Goldenberg, I., A. J. Moss, and W. Zareba. 2006. QT interval: how to measure it and what is "normal". J. Cardiovasc. Electrophysiol. 17:333-336. (Pubitemid 43344951)
18. Hatz, C., et al. 2008. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg. 78:241-247. (Pubitemid 351844558)
19. Khoo, S., D. Back, and P. Winstanley. 2005. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 19:995-1005. (Pubitemid 40961139)
20. Lefèvre, G., et al. 2000. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharm. Sci. 10:141-151. (Pubitemid 30155936)
21. Lefèvre, G., et al. 2002. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 54:485-492. (Pubitemid 35356874)
22. Masters, P. A., T. A. O'Bryan, J. Zurlo, D. Q. Miller, and N. Joshi. 2003. Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 163:402-410. (Pubitemid 36241016)
23. McGready, R., et al. 2008. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 5:e253.
24. Noedl, H., et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
25. Piola, P., et al. 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365:1467-1473. (Pubitemid 40591691)
26. Pozniak, A. L., M. Boffito, D. Russell, C. E. Ridgway, and G. J. Muirhead. 2008. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br. J. Clin. Pharmacol. 65(Suppl. 1):54-59. (Pubitemid 351366539)
27. Price, R. N., et al. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42:1570-1577.
28. Rahman, M. M., et al. 2008. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans. R. Soc. Trop. Med. Hyg. 102:861-867.
29. Sekar, V., et al. 2009. Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 68:116-119.
30. South African National Department of Health. 2004. National antiretroviral treatment guidelines, 1st ed. Jacana, Pretoria, South Africa.
31. Stockley, I. H. (ed.). 2002. Stockley's drug interactions, 6th ed. Pharmaceutical Press, Nottingham, United Kingdom.
32. Svensson, U. S., H. Alin, M. O. Karlsson, Y. Bergqvist, and M. Ashton. 2002. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur. J. Clin. Pharmacol. 58:339-351. (Pubitemid 34983925)
33. Tang, C., J. H. Lin, and A. Y. Lu. 2005. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab. Dispos. 33:603-613. (Pubitemid 40593872)
34. Tie, H., et al. 2000. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br. J. Pharmacol. 130:1967-1975. (Pubitemid 30655810)
35. United States National Library of Medicine. Artemether, ChemIDplus Advanced. National Institutes of Health, Bethesda, MD. http://chem.sis.nlm.nih. gov/chemidplus/. Accessed 16 September 2011.
36. United States National Library of Medicine. Dihydroartemisinin, ChemIDplus Advanced. National Institutes of Health, Bethesda, MD. http://chem.sis.nlm.nih.gov/chemidplus/. Accessed 16 September 2011.
37. van Agtmael, M. A., S. Cheng-Qi, J. X. Qing, R. Mull, and C. J. van Boxtel. 1999. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int. J. Antimicrob. Agents 12:151-158. (Pubitemid 29276919)
38. van Agtmael, M. A., V. Gupta, C. A. A. van der Graaf, and C. J. van Boxtel. 1999. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin. Pharmacol. Ther. 66(4):408-414. (Pubitemid 29494134)
39. Van Geertruyden, J. P., J. Menten, R. Colebunders, E. Korenromp, and U. D'Alessandro. 2008. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar. J. 7:134.
40. White, N. J., et al. 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar. J. 8:253.
41. White, N. J., M. van Vugt, and F. Ezzet. 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:105-125.
42. Wilkinson, G. R. 2008. Membrane transporters and drug response, p. 26-42. In K. Parker, L. L. Brunton, D. Blumenthal, and I. Buxton (ed.), Goodman and Gilman's manual of pharmacology and therapeutics. McGraw-Hill, New York, NY.
43. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
44. World Health Organization. 2004. Technical consultation on malaria and HIV interactions and public health policy implications. World Health Organization, Geneva, Switzerland.